The complexity of addressing equity in COVID-19-related global health governance and population health research priorities in Canada: a multilevel qualitative study.

Publication date: Dec 05, 2024

Since COVID-19 emerged in 2020, the promotion of health equity, including in research, has further been challenged worldwide by both global health governance (GHG) processes and decisions, and national public health control measures. These global and national decisions have also led to the ‘covidization’ of health research agendas where resources have been massively channelled to address COVID-19, especially during the first years of the pandemic. This situation could potentially result in current and future population health research priorities not explicitly tackling equity as a central tenet. The study objective examined how and to what extent the COVID-19-related GHG architecture is affecting population health research priorities in Canada. We conducted a multilevel qualitative study informed by the intersectionality-based policy analysis and multiple streams frameworks. We collected and thematically analysed data from four groups of respondents (nā€‰=ā€‰35: researchers, research funders and global and public health research institutes in Canada, and WHO/international actors) and an interactive feedback workshop (nā€‰=ā€‰40 participants). Study findings generated four main themes. First, both global and national COVID-19 responses failed to address equity considerations, especially among populations in situations of vulnerability and marginalisation. Second, the integrated examination of funding, equity, and accountability was judged as necessary determinants of GHG and population health research priorities in Canada. Third, contrary to common beliefs about COVID-19, the consequences were not all negative, but they were also positive and unintended, and lessons can be learned. Fourth, study respondents proposed multiple recommendations to address inequities in the complex intersection between COVID-19-related GHG and population health research in Canada. This study provides substantial evidence of the multilayered and complex intersection between COVID-19-related GHG and population health research priorities in Canada. Although the window of opportunity was slim according to study respondents, there was still a unique collective effort to address COVID-19-related socioeconomic and health inequities by considering the numerous recommendations proposed by the four groups of study respondents. These recommendations can directly contribute to improving knowledge of global and national population health and equity research strategies in the context of an evolving pandemic and for policy- and decision-makers to adjust and rectify the course of global and public health governance.

Open Access PDF

Concepts Keywords
Canada Accountability
Global Canada
Pandemic Canada
Researchers COVID-19
COVID-19
Covidization
Equity
Funding
Global Health
Global Health Governance
Health Equity
Health Priorities
Humans
Intersectionality
Multiple streams Framework
Population Health
Population Health Research
Qualitative Research

Semantics

Type Source Name
disease MESH COVID-19
disease MESH health inequities
pathway REACTOME Reproduction
drug DRUGBANK Cysteamine
disease MESH Tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Coenzyme M
drug DRUGBANK Amlodipine
drug DRUGBANK Trestolone
disease MESH Infectious diseases
disease MESH emergency
disease MESH sequelae
disease MESH non communicable diseases
drug DRUGBANK Isoxaflutole
drug DRUGBANK Methionine
drug DRUGBANK Icodextrin
drug DRUGBANK Nonoxynol-9
disease MESH Avian Flu
disease IDO history
disease MESH influenza
disease MESH emerging infectious diseases
disease MESH tic
drug DRUGBANK Albendazole
disease MESH causes
disease IDO production
drug DRUGBANK Ilex paraguariensis leaf
disease IDO intervention
drug DRUGBANK Water
drug DRUGBANK Tretamine
disease MESH recurrence
disease IDO contact tracing
disease IDO country
disease MESH privacy
drug DRUGBANK Serine
disease MESH Violence
disease IDO quality
drug DRUGBANK Ribostamycin
drug DRUGBANK Tropicamide
drug DRUGBANK Ademetionine

Original Article

(Visited 1 times, 1 visits today)